Latest news with #CapstanTherapeutics
Yahoo
08-07-2025
- Business
- Yahoo
AbbVie to Acquire Capstan Therapeutics for $2.1B, Boosting Autoimmune Pipeline
AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up to $2.1 billion in cash. The acquisition will expand AbbVie's product pipeline, particularly in experimental treatments for autoimmune diseases. Capstan Therapeutics Inc. is a clinical-stage biotechnology company that specializes in developing CAR-T therapies. These therapies use a patient's immune cells, specifically T-cells, to combat diseases. The lead asset is CPTX2309, which is currently in early-stage (Phase 1) clinical development for B-cell-mediated autoimmune diseases. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie will also acquire Capstan's CellSeeker tLNP platform technology, which is designed to deliver RNA payloads, such as mRNA, to engineer cell types in vivo. AbbVie is already projected to make over $31 billion in sales by 2027 with its autoimmune drugs Skyrizi and Rinvoq combined. AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that researches, develops, manufactures, commercializes, and sells medicines and therapies worldwide. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
02-07-2025
- Business
- Globe and Mail
Will AbbVie's Acquisition Spree Aid Pipeline Growth?
AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology remains its core area, the company is also signing some early-stage deals across various other therapeutic areas, including oncology and neuroscience. Earlier this week, AbbVie signed a definitive agreement to acquire privately held biotech Capstan Therapeutics for a total deal value of nearly $2.1 billion. The transaction, expected to be completed in the third quarter, will add Capstan's lead asset, CPTX2309 — a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy — to its immunology pipeline. The acquisition will also add Capstan's proprietary tLNP platform technology, CellSeeker, which helps deliver RNA, like mRNA, to engineer specific cell types inside the body. Since the beginning of last year, the company has signed over 20 early-stage deals, including promising technologies and innovative mechanisms that can elevate the standard of care across various therapeutic areas. Earlier this year, AbbVie acquired rights to develop a long-acting amylin analog for the treatment of obesity from Denmark's Gubra, marking its foray into the obesity space. It also plans to invest further in obesity. Among some recent larger deals, AbbVie acquired ImmunoGen, which added the ovarian cancer drug Elahere and neuroscience drugmaker Cerevel Therapeutics last year. These acquisitions have not only broadened AbbVie's therapeutic footprint but also diversified its pipeline across multiple modalities. The augmented pipeline now includes next-generation immunology candidates, bispecifics, antibody-drug conjugates and innovative therapies for neuropsychiatric and neurodegenerative disorders. We believe ABBV will continue pursuing such deals to further grow its pipeline. Focus on M&A in 2025 While broader macroeconomic concerns, including Trump-era tariffs and leadership shifts at the FDA, have weighed on deal-making this year, Big Pharma continues to pursue strategic assets in key growth areas. Last month, Eli Lilly LLY announced its intent to acquire cardiology-focused Verve Therapeutics in a deal valued at up to $1.3 billion. This transaction, which is also expected to close in the third quarter, will mark LLY's third targeted M&A deal this year. Earlier in January, it signed a $2.5 billion deal for Scorpion Therapeutics' experimental oncology drug. In May, Lilly agreed to acquire SiteOne Therapeutics for $1 billion to strengthen its neuroscience pipeline. Such deals suggest that LLY's M&A strategy is selective, focusing on long-term strength across therapeutic areas beyond its dominant presence in obesity. In June, Sanofi SNY announced a $9.5 billion acquisition of Blueprint Medicines to strengthen its immunology pipeline and reduce reliance on the blockbuster drug Dupixent. Through this transaction, SNY intends to add Ayvakit — an inhibitor of KIT and PDGFRA proteins with growing commercial traction — and several early-stage pipeline assets focused on systemic mastocytosis (SM). Recently, Sanofi completed the acquisition of an investigational bispecific antibody targeting autoimmune diseases from California-based Dren Bio and also agreed to acquire neurology-focused Vigil Neuroscience in a deal valued at around $470 million. ABBV's Price Performance, Valuation and Estimates Shares of AbbVie have outperformed the industry year to date, as seen in the chart below. From a valuation standpoint, AbbVie is not very cheap. Based on the price/earnings (P/E) ratio, the company's shares currently trade at 14.42 times forward earnings, slightly lower than its industry's average of 14.86. The stock is cheaper than some other large drugmakers, such as Eli Lilly and Novo Nordisk, but priced much higher than most other large drugmakers. The stock is also trading above its five-year mean of 12.46. The Zacks Consensus Estimate for 2025 EPS has risen from $12.26 to $12.28, while that for 2026 has remained consistent at $14.06 over the past 60 days. AbbVie currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Yahoo
01-07-2025
- Business
- Yahoo
AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline
AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a 'high-risk, high-reward' clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T therapy that overcomes limitations with current options. Currently approved therapies of this kind act by upgrading patient-extracted T cells' ability to fight cancer cells, but this method has financial and scalability hurdles, along with a lymphodepleting chemo requirement, curbing uptake. Capstan's lead asset, CPTX2309, is an in vivo targeted lipid nanoparticle (LNP) anti-CD19 CAR-T therapy that could solve these issues. AbbVie certainly sees the promise in the drug, paying $2.1bn upfront to take control of the CAR-T therapy alongside other preclinical programmes and the RNA payload-delivering technology used to create them. CPTX2309, being developed for the treatment of B-cell-mediated autoimmune diseases, is already being evaluated in a Phase I study (NCT06917742) with healthy volunteers. A preliminary look at the data from Capstan has revealed strong B-cell depletion – the aim of the treatment is to achieve an 'immune reset' by repopulation of healthy B cells. Investors shared positive sentiment in the acquisition, with shares in NYSE-listed AbbVie closing 1.7% higher at $185.62 on 30 June, the day the announcement was made. The big pharma has a market cap of $327.9bn. This is not the first in vivo CAR-T relationship that AbbVie has fostered, with a collaboration with Umoja Biopharma in January 2024. This partnership allows AbbVie to develop in-situ generated CAR-T cell therapy candidates in oncology using Umoja's VivoVecplatform. William Blair analyst Matt Phipps said in a research note: 'While CPTX2309 is still in early clinical development, we believe the acquisition shows a strategic effort by AbbVie to further strengthen its immunology franchise through novel, disease-modifying mechanisms. 'Given the stage of development, this asset clearly comes with clinical risk, but given the potential of in vivo CAR-T, which does not require lymphodepletion and has potential for greater manufacturing scalability, it offers significant long-term upside if successful.' Phipps, who described AbbVie's new asset as 'high-risk, high-reward,' said the purchase consolidates AbbVie's strong trading. The big pharma company has already shrugged off the loss of market exclusivity for its blockbuster Humira (adalimumab) by rolling out Skyrizi (risankizumab) and Rinvoq (upadacitinib). According to William Blair, forecast revenue rate from 2024 to 2029 growth rate for AbbVie trails only Eli Lilly and Sanofi, representing an 'attractive opportunity' for long-term investors. Capstan's CEO Laura Shawver said: "In vivo CAR-T represents a potential new treatment modality in medicine – embodying the transformative power of cell therapy with the accessibility and scalability of an off-the-shelf biologic. This technology has the potential to become a first-in-class platform to treat a wide range of autoimmune diseases.' Interius BioTherapeutics and Umoja Biopharma are two biotechs in the in vivo CAR-T arena that have assets in clinical trials targeting oncological indications. These assets also use lentiviral vectors to generate the cells in vivo, whereas Capstan is using mRNA. CPTX2309 is built on Capstan's targeted LNP platform to enable in vivo delivery of RNA payloads to target cells. CPTX2309 is made up of an anti-CD19 CAR mRNA payload inside an LNP. AbbVie's purchase comes just a few days after the US Food and Drug Administration (FDA) removed an access barrier for currently approved CAR-T therapies, regarded as a boost to the sector's outlook. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. "AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
01-07-2025
- Business
- Business Insider
AbbVie Stock (ABBV) Jumps on $2.1B Capstan Therapeutics Deal
AbbVie (ABBV) stock rallied on Monday after the company announced its $2.1 billion agreement to acquire Capstan Therapeutics. It will use cash to fund this transaction, which still needs to complete customary closing conditions before it's finalized. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. AbbVie's interest in Capstan Therapeutics has to do with CPTX2309. This is a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate undergoing a Phase 1 clinical trial. It's designed to treat B cell-mediated autoimmune diseases, which occur when the body's own immune system attacks it. This would reset the immune system, curing the disease instead of just treating its symptoms. Laura Shawver, Ph.D., President and CEO of Capstan Therapeutics, said, 'Through AbbVie's world-leading expertise in immunology research, clinical development, and its commercialization capabilities, we believe that this transaction moves us closer to delivering on our shared mission to bring these innovative therapies to patients in need.' AbbVie Stock Movement Today ABBV stock was up 1.5% as of this writing, suggesting investors were pleased with its planned purchase of Capstan Therapeutics. This also extended its 6.08% year-to-date rally and 7.01% rise over the past 12 months. Today's news saw some 1 million shares traded, which is still below the company's three-month daily average trading volume of about 5.89 million units. Is AbbVie Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for AbbVie is Moderate Buy, based on 11 Buy and six Hold ratings over the past three months. With that comes an average ABBV stock price target of $212.80, representing a potential 14.86% upside for the shares. Spark, TipRanks' AI analyst, cites 'strong financial performance, particularly in cash flow generation and operational profitability, coupled with positive earnings call highlights' as the reasons behind its Buy rating for ABBV stock.
CNBC
30-06-2025
- Business
- CNBC
AbbVie to buy Capstan Therapeutics for up to $2.1 billion
AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to $2.1 billion. Capstan develops CAR-T therapies, a type of treatment that uses a patient's own immune cells, specifically T cells, to fight diseases. Its main drug, CPTX2309, is currently in development for the treatment of autoimmune diseases. AbbVie has been focusing on expanding its pipeline since its blockbuster arthritis drug, Humira, lost patent protection last year.
